Clinical Trials
146 trialsA Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
National Cancer Institute (NCI)
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma
Northwestern University
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
Fox Chase Cancer Center
ACCELERATE
New York Medical College
Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
M.D. Anderson Cancer Center
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
St. Jude Children's Research Hospital
Drug Screening Using IMD in Bladder Cancer
Brigham and Women's Hospital
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
National Cancer Institute (NCI)
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
National Cancer Institute (NCI)
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
St. Jude Children's Research Hospital
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
AstraZeneca
RADAR
University College, London
Metro-PD1
Centre Oscar Lambret
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Takeda
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
Takeda
MK-3475-667
Merck Sharp & Dohme LLC
A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder
M.D. Anderson Cancer Center
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
Memorial Sloan Kettering Cancer Center
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
National Medical Research Radiological Centre of the Ministry of Health of Russia
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Takeda
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
University of Washington
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Seagen Inc.
FIL Study on ABVD DD-DI as Upfront Therapy in HL.
Fondazione Italiana Linfomi - ETS
PLGG - MEKTRIC
University Hospital, Strasbourg, France
RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease
European Organisation for Research and Treatment of Cancer - EORTC
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
University of Washington
Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
SAFIR02_Breast
UNICANCER
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
City of Hope Medical Center
HL-Russia-1
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
COXEN
SWOG Cancer Research Network
Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma
University College, London
EuroNetLP1
Martin-Luther-Universität Halle-Wittenberg
CheckMate 205
Bristol-Myers Squibb
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
St. Jude Children's Research Hospital
Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Stanford University
Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
Canadian Cancer Trials Group
H-9926-LCH III: Treatment Protocol of the Third International Study for Langerhans Cell Histiocytosis
University of New Mexico
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
Eastern Cooperative Oncology Group
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Eastern Cooperative Oncology Group
Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma
Eastern Cooperative Oncology Group
Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium
Eastern Cooperative Oncology Group
Combination Chemotherapy in Treating Patients With Bladder Cancer
Eastern Cooperative Oncology Group
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
Northwestern University
SFCE METRO 01
Assistance Publique Hopitaux De Marseille